HIV NC 2018
(O1) HPV genotypes identified in migrant women living with HIV are not covered for by current HPV vaccines; results from an interim analysis
(O2) Frequency of co-expression of inhibitory receptors early in HIV infection determines progression rate in untreated patients.
(O3) Switching to FTC/TAF from either ABC/3TC or FTC/TDF does not affect central nervous system HIV-1 infection
(O4) Gut mucosal CD4 T cells of immunological non-responders with low CD4/CD8 ratio have increased cytokine production, which may be reduced by probiotics
(O5) Acute Hepatitis E Virus Genotype 3 Infection Associated with Acute Pancreatitis
(O6) Enhancing the hepatitis C (HCV) care cascade for people who inject drugs (PWID) at the Stockholm needle exchange
(P7) Quantification of transcriptional-competent latent HIV-1 reservoir in a subtype independent manner using RNAscope at a single-cell resolution
(P8) Vitamin D and phenylbutyrate supplementation does not modulate gut derived immune activation in HIV-1
(P9) Bone, renal and inflammatory biomarkers up to week 100 post switch to DTG + RPV: the SWORD-1 and SWORD-2 studies
(P10) Frequent and Long Lasting V1V2 Antibody Responses Induced by HIV-DNA Priming Followed by HIV-MVA Boosting in Healthy Tanzanian Volunteers
(P11) Review of HIV testing recommendations for HIV indicator conditions in guidelines from Danish national health authorities and medical specialties
(P12) The Syphilis epidemic among men who have sex with men (MSM) in Stockholm 1998-2017
(P13) The HIV Care Continuum among female sex workers in Guinea-Bissau, West Africa
(P14) Masibambisane Madoda : What do young men want in a sexual healthcare service?
(P15) The microbial metabolite TMAO in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages
(P16) Smoking and increased hsCRP are important factors for severe cardiovascular disease (CVD) in HIV-infection
(P17) To better understand the function of early Env-specific CTLs
(P18) A diverse HIV subtype distribution and high pretreatment drug resistance in newly diagnosed patients in Sweden, 2017-2018
(P19) Plasma CD163 and FABP4 are biomarkers associated with residual liver disease and fibrosis recovery during DAA treatment of chronic HCV infection
(P20) PREVALENCE OF RENAL FINDINGS AMONG PATIENT AND CONTROL POPULATIONS IN THE HCVKID-STUDY: FIRST INTERIM ANALYSIS
(P21) Effect of baseline Y93H in HCV GT 3 for DAA treatment: Real-life experience from a multicenter study in Sweden and Norway 2014-17
(P22) A DNA-based immunotherapy induces receptor-blocking antibodies that can neutralize HBV in humanized mice
(P23) Cell culture derived genotype 5a HCV particles formulated with human adjuvants elicit neutralizing antibodies in immunized mice
(P24) Adherence to Danish national treatment guideline recommendations on treatment initiation in Chronic Hepatitis B patients
(P25) Models of Care: Strategies towards Elimination of Hepatitis C in Iceland